Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Go back to Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
(NASDAQ: VIR) Delayed: 10.73 +0.16 (1.51%)
Previous Close $10.57    52 Week High $ 
Open $10.60    52 Week Low $ 
Day High $10.73    P/E N/A 
Day Low $10.60    EPS $ 
Volume 50,835